Dr. Ronan Thomas Swords, MD

Dr. Swords practices at OHSU Hospital in Portland, Oregon, part of State of Oregon.

Dr. Swords' NPI, 1720216401, was assigned on July 1, 2009. Dr. Swords holds Oregon license MF200792.

Dr. Swords' primary practice is OHSU Hospital, at 3181 SW Sam Jackson Park Road, Portland, OR 97239 in Multnomah County. The practice phone is (503) 494-9000.

Dr. Swords' primary practice is OHSU Hospital in Portland, Oregon, part of State of Oregon. Dr. Swords is also affiliated with Adventist Health Portland. The medical group on file is Oregon Health & Science University (OHSU). Dmand AI also links Dr. Swords to 2 more hospitals, 1 clinical lab and 1 group practice or clinic, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Swords practices, 6 sites in all. Vendor and product names are available with a free account.

Internal medicine is Dr. Swords' primary specialty in the NPI Registry, under taxonomy code 207RH0000X. The record also lists hematology. Dmand AI has Dr. Swords' licenses on file in 2 states: Oregon and Florida.

CMS data shows 827 Medicare services from Dr. Swords across 5 procedure codes in 2024, for 146 Medicare patients. Medicare paid $61,181 for them.

CMS counts 146 Medicare patients who saw Dr. Swords in 2024. The largest group is 65 to 74, with 73 patients. 68% of them have high blood pressure, and 62% have high cholesterol. 13% are also on Medicaid. Their average risk score is 2.77, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Swords' median patient age at 75, with 38% women.

In 2024, Dr. Swords wrote 847 Medicare Part D claims for 69 patients. 83% of them were for generic drugs. CMS names the drug for 642 of them, across 23 drugs with 11 or more claims each, at $860,628 in total drug cost. In 2023, CMS named 567 claims across 17 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 99 out of 100 for Dr. Swords for performance year 2024, reported through an alternative payment model (APM). Dr. Swords accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Swords as offering telehealth.

Dmand AI links 53 papers to Dr. Swords, published from 2011 to 2025. 2017 was the busiest year, with 8. The most frequent topics are Leukemia, Myeloid, Acute, Antineoplastic Agents and Molecular Targeted Therapy. Dr. Swords has published most often in Leuk Lymphoma. Dr. Swords' most frequent co-authors are Francis J. Giles, MD, Justin M. Watts, MD and Elie A. Traer, MD, PhD.

Dmand AI links Dr. Swords to 1 clinical trial. Conditions studied include Leukemia, Myelomonocytic, Chronic and Myelodysplastic-Myeloproliferative Diseases. Open Payments lists research payments to Dr. Swords that name 1 trial.

CMS Open Payments shows 89 general payments to Dr. Swords from 14 drug and device companies from 2016 to 2023. Consulting fees make up the largest share, 58% of the total. Abbvie Inc. paid the most, $8,720. It also lists 3 research payments totaling $4,117 from 2016 to 2017, naming 1 clinical trial.